Robust In Vitro HPLC-DAD Method for Accurate Quantification of N-Carbamylglutamate in Drug Formulations

Year 2024, Volume: 44 Issue: 4, 337 - 350, 01.12.2024

Burak Arabacı , Nursabah Elif Başcı Akduman

https://doi.org/10.52794/hujpharm.1560541

Abstract

A comprehensive in vitro testing method has been developed and validated for accurately quantifying N-Carbamylglutamate (Carglumic acid) using a high-performance liquid chromatography instrument with a diode array detector. A method specifically developed for pharmaceutical quality control utilizes a reverse-phase C18 column for precise and reliable measurement of Carglumic acid. The chromatographic parameters were refined for peak resolution, employing a phosphate buffer and acetonitrile as the mobile phase, with detection setup at 205 nm. The method was validated under ICH Q2(R2) requirements. The approach exhibited a significant level of specificity, with no interference from excipients or other possible impurities. Linearity was achieved across the entire concentration range, yielding an R² value of 0.999. Precision (RSD ≤ 2) was demonstrated by intra- and inter-day variability being within acceptable limits. Recovery tests validated accuracy (98 – 102%). Determining the limit of detection (LOD, 0.1 ppm) and the limit of quantitation (LOQ, 0.5 ppm) was conducted. This in vitro test method was valid and effective for the routine quantification of Carglumic acidin pharmaceutical formulations, serving as a crucial tool for ensuring product quality and regulatory compliance. The methods' elevated sensitivity and endurance make it appropriate for bioanalytical applications, such as dissolution testing and stability analysis.

Keywords

Carglumic Acid, N-Carbamylglutamate, in-vitro, N-carbamylglutamate dissolution

References

• 1. Levrat V, Forest I, Fouilhoux A, Acquaviva C, Vianey-Saban C, Guffon N. Carglumic acid: An additional therapy in the treatment of organic acidurias with hyperammonemia? Orphanet J Rare Dis 2008;3. https://doi.org/10.1186/1750-1172-3-2
• 2. Sattar Y, Wasiq S, Yasin W, Khan AM, Adnan M, Shrestha S, et al. Carglumic Acid Treatment of a Patient with Recurrent Valproic Acid-induced Hyperammonemia: A Rare Case Report. Cureus 2018. https://doi.org/10.7759/cureus.3292
• 3. Abacan M, Boneh A. Use of carglumic acid in the treatment of hyperammonaemia during metabolic decompensation of patients with propionic acidaemia. Mol Genet Metab 2013;109:397–401. https://doi.org/10.1016/j.ymgme.2013.05.018
• 4. Alfadhel M, Nashabat M, Saleh M, Elamin M, Alfares A, Al Othaim A, et al. Long-term effectiveness of carglumic acid in patients with propionic acidemia (PA) and methylmalonic acidemia (MMA): a randomized clinical trial. Orphanet J Rare Dis 2021;16. https://doi.org/10.1186/s13023-021-02032-8
• 5. Valayannopoulos V, Baruteau J, Delgado MB, Cano A, Couce ML, Del Toro M, et al. Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk-benefit profile: A retrospective observational study. Orphanet J Rare Dis 2016;11. https://doi.org/10.1186/s13023-016-0406-2
• 6. Carglumic acid: new preparation. An advance in rare urea cycle disorders. Prescrire Int 2004;13:3–4
• 7. Carglumic acid: a second look. Confirmed progress in a rare urea cycle disorder. Prescrire Int 2008;17:50–1
• 8. Sharma P, Shah PA, Sanyal M, Shrivastav PS. Challenges in optimizing sample preparation and LC-MS/MS conditions for the analysis of carglumic acid, an N-acetyl glutamate derivative in human plasma. Drug Test Anal 2015;7:763–72. https://doi.org/10.1002/dta.1774
• 9. Daniotti M, la Marca G, Fiorini P, Filippi L. New developments in the treatment of hyperammonemia: Emerging use of carglumic acid. Int J Gen Med 2011;4:21–8. https://doi.org/10.2147/IJGM.S10490
• 10. Kiykim E, Zubarioglu T. Low dose of carglumic acid for treatment of hyperammonemia due to N-acetylglutamate synthase deficiency. Indian Pediatr 2014;51:755–6
• 11. United States Pharmacopeia. USP-NF Carglumic Acid. PF 47(6) n.d.
• 12. Hart EJ, Powers-Lee SG. Role of Cys-1327 and Cys-1337 in Redox Sensitivity and Allosteric Monitoring in Human Carbamoyl Phosphate Synthetase. Journal of Biological Chemistry 2009;284:5977–85. https://doi.org/10.1074/jbc.M808702200
• 13. Kasapkara CS, Ezgu FS, Okur I, Tumer L, Biberoglu G, Hasanoglu A. N-carbamylglutamate treatment for acute neonatal hyperammonemia in isovaleric acidemia. Eur J Pediatr 2011;170:799–801. https://doi.org/10.1007/s00431-010-1362-9
• 14. National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 121396, Carglumic Acid.Https://PubchemNcbiNlmNihGov/Compound/Carglumic-Acid n.d.
• 15. SrinivasaRao D, Venkateswarlu T, Rama Krishna G. International Journal of Pharmaceutical, Chemical and Biological Sciences Development and Validation of HPLC Method of Dissolution Test for Metoprolol Succinate and Cilnidipine. Int J Pharm Chem Biol Sci n.d.;2015:971–81
• 16. Xu X, Gupta A, Faustino P, Sathe PM, Sayeed VA, Khan MA. Development and Validation of a HPLC Method for Dissolution and Stability Assay of Liquid-Filled Cyclosporine Capsule Drug Products. AAPS PharmSciTech 2013;14:959–67. https://doi.org/10.1208/s12249-013-9983-8
• 17. Upadhyay Y, Sharma N, Sarma GS, Rawal RK. Application of RP-HPLC method in dissolution testing and statistical evaluation by NASSAM for simultaneous estimation of tertiary combined dosages forms. J Pharm Anal 2015;5:307–15. https://doi.org/10.1016/j.jpha.2014.11.001
• 18. Xu X, Gupta A, Faustino P, Sathe PM, Sayeed VA, Khan MA. Development and validation of a HPLC method for dissolution and stability assay of liquid-filled cyclosporine capsule drug products. AAPS PharmSciTech 2013;14:959–67. https://doi.org/10.1208/s12249-013-9983-8
• 19. Arisoy S, Sayiner Ö, Çomoğlu T. Development and Validation of an In Vitro; Dissolution Method Based on HPLC Analysis for L-Dopa Release From PLGA Nanoparticles. Bezmialem Science 2021;9:9–19. https://doi.org/10.14235/bas.galenos.2020.3860
• 20. Cao W, Xiao L, Liu G, Fang T, Wu X, Jia G, et al. Dietary arginine and: N -carbamylglutamate supplementation enhances the antioxidant statuses of the liver and plasma against oxidative stress in rats. Food Funct 2016;7:2303–11. https://doi.org/10.1039/c5fo01194a
• 21. Tuchman M. N-carbamylglutamate Markedly Enhances Ureagenesis in N-acetylglutamate Deficiency and Propionic Acidemia as Measured by Isotopic Incorporation and Blood Biomarkers. 2008. https://doi.org/10.1203/PDR.0b013e318179454b
• 22. Arabaci B, Yerlikaya F, Basci Akduman NE. A Novel Method for Development and Validation of the Degradation Products Analysis of N-Carbamylglutamate with UHPLC by Using Design of Experiment Approach. ACS Omega 2024. https://doi.org/10.1021/acsomega.4c01183
• 23. Frank JW, Escobar J, Nguyen H V, Jobgen SC, Jobgen WS, Davis TA, et al. The Journal of Nutrition Nutrient Physiology, Metabolism, and Nutrient-Nutrient Interactions Oral N-Carbamylglutamate Supplementation Increases Protein Synthesis in Skeletal Muscle of Piglets 1. vol. 137. 2007. https://doi.org/10.1093/jn/137.2.315
• 24. Debrus B, Guillarme D, Rudaz S. Improved quality-by-design compliant methodology for method development in reversed-phase liquid chromatography. J Pharm Biomed Anal 2013;84:215–23. https://doi.org/10.1016/j.jpba.2013.06.013
• 25. ICH. Analytical Procedure Development Q14. 2022
• 26. Sathuluri K, Bakam R, Jain R, Dande A, Gajbhiye R, Ravichandiran V, et al. Analytical quality by design (AQbD) in the ICHQ14 guidelines for analytical procedure development. Accreditation and Quality Assurance 2024. https://doi.org/10.1007/s00769-024-01587-w
• 27. ICH. Committee for Medicinal Products for Human Use ICH Q2(R2) Guideline on validation of analytical procedures. 2023
• 28. ICH. International Conference on Harmonization of Technical Requirements for registration of pharmaceuticals for human use. Harmonised Guideline Quality Risk Management Q9(R1). 2023
• 29. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Ich Harmonised Tripartite Guideline Validation of Analytical Procedures: Text and Methodology Q2(R1). 2005
• 30. ICH. ICH guideline Q4B annex 7 (R2) to note for evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on dissolution test-general chapter. 2010
• 31. Marzouk HM, Rezk MR, Gouda AS, Abdel-Megied AM. A novel stability-indicating HPLC-DAD method for determination of favipiravir, a potential antiviral drug for COVID-19 treatment; application to degradation kinetic studies and in-vitro dissolution profiling. Microchem J 2022;172:106917. https://doi.org/10.1016/j.microc.2021.106917
• 32. Sahu PK, Ramisetti NR, Cecchi T, Swain S, Patro CS, Panda J. An overview of experimental designs in HPLC method development and validation. J Pharm Biomed Anal 2018;147:590–611. https://doi.org/10.1016/j.jpba.2017.05.006
• 33. Fda. Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances Guidance for Industry. 2018
• 34. Lee JS, Feijen J. Polymersomes for drug delivery: Design, formation and characterization. Journal of Controlled Release 2012;161:473–83. https://doi.org/10.1016/j.jconrel.2011.10.005
• 35. Talelli M, Barz M, Rijcken CJF, Kiessling F, Hennink WE, Lammers T. Core-crosslinked polymeric micelles: Principles, preparation, biomedical applications and clinical translation. Nano Today 2015;10:93–117. https://doi.org/10.1016/j.nantod.2015.01.005
• 36. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012;41:2971. https://doi.org/10.1039/c2cs15344k
• 37. Croissant JG, Fatieiev Y, Khashab NM. Degradability and Clearance of Silicon, Organosilica, Silsesquioxane, Silica Mixed Oxide, and Mesoporous Silica Nanoparticles. Advanced Materials 2017;29. https://doi.org/10.1002/adma.201604634.
• 38. Kassem AA, Abd El-Alim SH, Basha M, Salama A. Phospholipid complex enriched micelles: A novel drug delivery approach for promoting the antidiabetic effect of repaglinide. Eur J Pharm Sci 2017;99:75–84.https://doi.org/10.1016/j.ejps.2016.12.005.
• 39. Butt S, Hasan SMF, Hassan MM, Alkharfy KM, Neau SH. Directly compressed rosuvastatin calcium tablets that offer hydrotropic and micellar solubilization for improved dissolution rate and extent of drug release. Saudi Pharm J 2019;27:619–28. https://doi.org/10.1016/j.jsps.2019.03.002
• 40. Sahle FF, Balzus B, Gerecke C, Kleuser B, Bodmeier R. Formulation and in vitro evaluation of polymeric enteric nanoparticles as dermal carriers with pH-dependent targeting potential. European Journal of Pharmaceutical Sciences 2016;92:98–109. https://doi.org/10.1016/j.ejps.2016.07.004
• 41. Lovskaya DD, Lebedev AE, Menshutina NV. Aerogels as drug delivery systems: In vitro and in vivo evaluations. J Supercrit Fluids 2015;106:115–21. https://doi.org/10.1016/j.supflu.2015.07.011
• 42. Takagi T, Ramachandran C, Bermejo M, Yamashita S, Yu LX, Amidon GL. A Provisional Biopharmaceutical Classification of the Top 200 Oral Drug Products in the United States, Great Britain, Spain, and Japan. Mol Pharm 2006;3:631–43. https://doi.org/10.1021/mp0600182
• 43. Yu LX. Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control. Pharm Res 2008;25:781–91. https://doi.org/10.1007/s11095-007-9511-1
• 44. Amidon GL, Lennernäs H, Shah VP, Crison JR. A Theoretical Basis for a Biopharmaceutic Drug Classification - The Correlation of In-Vitro Drug Product Dissolution and In-Vivo Bioavailability. Pharm Res 1995;12:413–20. https://doi.org/10.1023/A:1016212804288
• 45. USP <711> Dissolution. Stage 6 Harmonization. Official December 1, 2011.
• 46. USP-NF (1088) in Vitro and in Vivo Evaluation of Oral Dosage Forms n.d.
• 47. USP-NF (1711) Oral Dosage Forms—Performance Tests n.d.
• 48. USP-NF (724) Drug Release n.d.
• 49. Singh RH, Rhead WJ, Smith W, Lee B, King LS, Summar M. Nutritional Management of Urea Cycle Disorders. Crit Care Clin 2005;21:S27–35. https://doi.org/10.1016/j.ccc.2005.08.003
• 50. Patel MN, Kothari CS. Multivariate approaches for simultaneous determination of avanafil and dapoxetine by UV chemometrics and HPLC-QbD in binary mixtures and pharmaceutical product. J AOAC Int 2016;99:649–63. https://doi.org/10.5740/jaoacint.15-0259
• 51. ACE UHPLC and HPLC Columns Cannabinoids in Rat Plasma Conditions. n.d.
• 52. Azhakesan A, Kuppusamy S. Analytical Quality by Design-Assisted HPLC Method for Quantification of Canagliflozin and Stability Studies. ACS Omega 2023;8:7407–14. https://doi.org/10.1021/acsomega.2c06038
• 53 Azhakesan A, Kuppusamy S. Analytical Quality by Design-Assisted HPLC Method for Quantification of Canagliflozin and Stability Studies. ACS Omega 2023;8:7407–14. https://doi.org/10.1021/acsomega.2c06038
• 54. Garg LK, Reddy VS, Sait SS, Krishnamurthy T, Vali SJ, Reddy AM. Quality by design: Design of experiments approach prior to the validation of a stability-indicating HPLC method for Montelukast. Chromatographia 2013;76:1697–706. https://doi.org/10.1007/s10337-013-2509-4
• 55. Mahrouse MA, Lamie NT. Experimental design methodology for optimization and robustness determination in ion pair RP-HPLC method development: Application for the simultaneous determination of metformin hydrochloride, alogliptin benzoate and repaglinide in tablets. Microchemical Journal 2019;147:691–706. https://doi.org/10.1016/j.microc.2019.03.038
• 56. Sharma S, Gupta P, Gupta A, Kawish S, Iqbal Z, Vohora D, et al. Rapid Analytical Method Development and Validation of RP-HPLC Method for the Simultaneous Estimation of Exemestane and Genistein with Specific Application in Lipid-Based Nanoformulations. ACS Omega 2023. https://doi.org/10.1021/acsomega.3c01791
• 57. Rozet E, Ziemons E, Marini RD, Boulanger B, Hubert P. Quality by design compliant analytical method validation. Anal Chem 2012;84:106–12. https://doi.org/10.1021/ac202664s
• 58. Sahu PK, Ramisetti NR, Cecchi T, Swain S, Patro CS, Panda J. An overview of experimental designs in HPLC method development and validation. J Pharm Biomed Anal 2018;147:590–611. https://doi.org/10.1016/j.jpba.2017.05.006
• 59. De Backer B, Debrus B, Lebrun P, Theunis L, Dubois N, Decock L, et al. Innovative development and validation of an HPLC/DAD method for the qualitative and quantitative determination of major cannabinoids in cannabis plant material. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:4115–24. https://doi.org/10.1016/j.jchromb.2009.11.004
• 60. Hussain A, Ramzan M, Altamimi MA, Khuroo T, Mohd Siddique MU, Alnemer OA. HSPiP, Computational Modeling, and QbD-Assisted Optimized Method Validation of 5-Fluorouracil for Transdermal Products. ACS Omega 2024;9:903–16. https://doi.org/10.1021/acsomega.3c07061
• 61. Kovač L, Časar Z, Trdan Lušin T, Roškar R. Development of an Analytical Method for Determination of Related Substances and Degradation Products of Cabotegravir Using Analytical Quality by Design Principles. ACS Omega 2022;7:8896–905. https://doi.org/10.1021/acsomega.1c07260
• 62. Pawar R, Naresh P, Kalva B, Kumar MR, Ravichandiran V, Ramalingam P. Analytical quality by design approach for the development of high-performance liquid chromatography method for simultaneous analysis of metformin and sitagliptin in the presence of major degradation products. J Sep Sci 2024;47. https://doi.org/10.1002/jssc.202300605
• 63. Prajapati P, Patel M, Shah S. A robust high-performance thin-layer chromatography method for the simultaneous estimation of chlorthalidone and metoprolol succinate using quality risk assessment and design of experiments-based enhanced analytical quality by design approach. J Planar Chromatogr - Modern TLC 2021;34:229–42. https://doi.org/10.1007/s00764-021-00107-7
• 64. USP-NF Reagents and Reference Tables, Solutions, Volumetric Solutions. n.d.
• 65. United States Pharmacopeia (2024). Reagents, Buffer Solutions. USP-NF. Rockville, MD: United States Pharmacopeia
• 66. Alberto Mattel, Marco Barchielli, Stefano Selva, Eduardo Bolzan, (2020), Pharmaceutical formulation for carglumic acid (WO2020239882A1)